Funda Meric-Bernstam

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/869094/publications.pdf

Version: 2024-02-01

498 papers	41,068 citations	2101 100 h-index	3915 177 g-index
514 all docs	514 docs citations	514 times ranked	46375 citing authors

#	Article	IF	Citations
1	Efficacy of Larotrectinib inTRKFusionâ€“Positive Cancers in Adults and Children. New England Journal of Medicine, 2018, 378, 731-739.	27.0	2,036
2	KRAS^{G12C} Inhibition with Sotorasib in Advanced Solid Tumors. New England Journal of Medicine, 2020, 383, 1207-1217.	27.0	1,049
3	PD-L1 Expression in Triple-Negative Breast Cancer. Cancer Immunology Research, 2014, 2, 361-370.	3.4	994
4	Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature, 2014, 512, 155-160.	27.8	911
5	Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer. Journal of Clinical Oncology, 2009, 27, 3297-3302.	1.6	795
6	Targeting the PI3K pathway in cancer: are we making headway?. Nature Reviews Clinical Oncology, 2018, 15, 273-291.	27.6	762
7	Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study. Journal of Clinical Oncology, 2008, 26, 4311-4318.	1.6	622
8	Pathogenic Germline Variants in 10,389 Adult Cancers. Cell, 2018, 173, 355-370.e14.	28.9	620
9	Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes. Clinical Cancer Research, 2013, 19, 5533-5540.	7.0	597
10	Targeting the mTOR Signaling Network for Cancer Therapy. Journal of Clinical Oncology, 2009, 27, 2278-2287.	1.6	587
11	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature, 2018, 554, 189-194.	27.8	572
12	Emergence of Constitutively Active Estrogen Receptor-Î± Mutations in Pretreated Advanced Estrogen Receptorâ€“Positive Breast Cancer. Clinical Cancer Research, 2014, 20, 1757-1767.	7.0	529
13	Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer. Clinical Cancer Research, 2011, 17, 1082-1089.	7.0	487
14	A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nature Communications, 2014, 5, 3887.	12.8	456
15	High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2â€“Positive, Node-Negative Tumors 1 cm or Smaller. Journal of Clinical Oncology, 2009, 27, 5700-5706.	1.6	404
16	Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2011, 29, 2645-2652.	1.6	400
17	Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. Nature Genetics, 2016, 48, 1119-1130.	21.4	396
18	Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. Journal of Clinical Oncology, 2015, 33, 2753-2762.	1.6	372

#	Article	IF	Citations
19	21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. New England Journal of Medicine, 2021, 385, 2336-2347.	27.0	363
20	Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. Journal of Clinical Oncology, 2018, 36, 536-542.	1.6	362
21	Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncology, The, 2019, 20, 518-530.	10.7	362
22	Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications. PLoS ONE, 2014, 9, e115383.	2.5	362
23	Breast Conservation After Neoadjuvant Chemotherapy: The M.D. Anderson Cancer Center Experience. Journal of Clinical Oncology, 2004, 22, 2303-2312.	1.6	359
24	Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer Cells. Clinical Cancer Research, 2004, 10, 7031-7042.	7.0	303
25	Biliary cancer: Utility of nextâ€generation sequencing for clinical management. Cancer, 2016, 122, 3838-3847.	4.1	289
26	Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes. Clinical Cancer Research, 2009, 15, 7381-7388.	7.0	281
27	Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nature Immunology, 2019, 20, 835-851.	14.5	277
28	Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: A guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. Journal of the American College of Surgeons, 2005, 200, 516-526.	0.5	272
29	Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy is Accurate and Reduces the Need for Axillary Dissection in Breast Cancer Patients. Annals of Surgery, 2009, 250, 558-566.	4.2	270
30	Determinants of Rapamycin Sensitivity in Breast Cancer Cells. Clinical Cancer Research, 2004, 10, 1013-1023.	7.0	269
31	Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome. Journal of Clinical Oncology, 2007, 25, 2650-2655.	1.6	253
32	Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. Cancer Discovery, 2018, 8, 164-173.	9.4	243
33	Effect of Primary Tumor Extirpation in Breast Cancer Patients Who Present With Stage IV Disease and an Intact Primary Tumor. Annals of Surgical Oncology, 2006, 13, 776-782.	1.5	238
34	Role for Intraoperative Margin Assessment in Patients Undergoing Breast-Conserving Surgery. Annals of Surgical Oncology, 2007, 14, 1458-1471.	1.5	229
35	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clinical Cancer Research, 2018, 24, 1062-1072.	7.0	225
36	Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. Clinical Cancer Research, 2019, 25, 2033-2041.	7.0	224

#	Article	IF	Citations
37	Accuracy of Physical Examination, Ultrasonography, and Mammography in Predicting Residual Pathologic Tumor Size in Patients Treated With Neoadjuvant Chemotherapy. Annals of Surgery, 2006, 243, 257-264.	4.2	217
38	Targeting TRK family proteins in cancer. , 2017, 173, 58-66.		217
39	Nanomedicine in cancer therapy: Innovative trends and prospects. Cancer Science, 2011, 102, 1247-1252.	3.9	216
40	Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell, 2018, 33, 450-462.e10.	16.8	213
41	Clinical and molecular characterization of earlyâ€onset colorectal cancer. Cancer, 2019, 125, 2002-2010.	4.1	212
42	Instruments to assess the quality of health information on the World Wide Web: what can our patients actually use?. International Journal of Medical Informatics, 2005, 74, 13-19.	3.3	210
43	PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer. Molecular Cancer Therapeutics, 2011, 10, 1093-1101.	4.1	204
44	A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clinical Proteomics, 2010, 6, 129-151.	2.1	203
45	Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet, The, 2021, 397, 1010-1022.	13.7	196
46	Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2â€positive breast cancer. Cancer, 2010, 116, 2884-2889.	4.1	194
47	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discovery, 2016, 6, 1352-1365.	9.4	192
48	PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors. Clinical Cancer Research, 2012, 18, 1777-1789.	7.0	191
49	Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer and Metastasis Reviews, 2016, 35, 547-573.	5.9	189
50	Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes. Oncotarget, 2014, 5, 9864-9876.	1.8	188
51	Landscape of DNA Virus Associations across Human Malignant Cancers: Analysis of 3,775 Cases Using RNA-Seq. Journal of Virology, 2013, 87, 8916-8926.	3.4	187
52	Metformin: A Therapeutic Opportunity in Breast Cancer. Clinical Cancer Research, 2010, 16, 1695-1700.	7.0	184
53	Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncology, The, 2021, 22, 1290-1300.	10.7	178
54	Rak Functions as a Tumor Suppressor by Regulating PTEN Protein Stability and Function. Cancer Cell, 2009, 15, 304-314.	16.8	175

#	Article	IF	Citations
55	State-of-the-Art Strategies for Targeting RET-Dependent Cancers. Journal of Clinical Oncology, 2020, 38, 1209-1221.	1.6	172
56	A Decision Support Framework for Genomically Informed Investigational Cancer Therapy. Journal of the National Cancer Institute, 2015, 107, .	6.3	168
57	Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Cancer, 2013, 119, 1776-1783.	4.1	166
58	Targeting the PI3-Kinase/Akt/mTOR Signaling Pathway. Surgical Oncology Clinics of North America, 2013, 22, 641-664.	1.5	161
59	American College of Surgeons Oncology Group (ACOSOG) Z0011: Impact on Surgeon Practice Patterns. Annals of Surgical Oncology, 2012, 19, 3144-3151.	1.5	157
60	The impact of pregnancy on breast cancer outcomes in women â‰35 years. Cancer, 2009, 115, 1174-1184.	4.1	154
61	Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer. JAMA Oncology, 2017, 3, 509.	7.1	154
62	Metastases to the breast from nonbreast solid neoplasms. Cancer, 2007, 110, 731-737.	4.1	151
63	Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience. Journal of Clinical Oncology, 2011, 29, 3739-3746.	1.6	151
64	Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Annals of Oncology, 2016, 27, 795-800.	1.2	150
65	Targeting AKT for cancer therapy. Expert Opinion on Investigational Drugs, 2019, 28, 977-988.	4.1	150
66	Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Investigational New Drugs, 2018, 36, 638-646.	2.6	149
67	Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2013, 14, 1317-1325.	10.7	148
68	First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. Cancer Discovery, 2021, 11, 80-91.	9.4	148
69	Low locoregional failure rates in selected breast cancer patients with tumorâ€positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer, 2007, 110, 723-730.	4.1	145
70	Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell, 2019, 36, 444-457.e7.	16.8	145
71	Breast tumours maintain a reservoir of subclonal diversity during expansion. Nature, 2021, 592, 302-308.	27.8	145
72	Effect of metformin on survival outcomes in diabetic patients with triple receptorâ€negative breast cancer. Cancer, 2012, 118, 1202-1211.	4.1	144

#	Article	IF	Citations
73	Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Research, 2019, 21, 78.	5.0	141
74	Factors Affecting the Decision of Breast Cancer Patients to Undergo Contralateral Prophylactic Mastectomy. Cancer Prevention Research, 2010, 3, 1026-1034.	1.5	138
75	Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. Journal of Investigative Dermatology, 2015, 135, 508-515.	0.7	138
76	BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell, 2006, 10, 145-157.	16.8	137
77	Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocrine-Related Cancer, 2008, 15, 257-266.	3.1	137
78	Impact of Preoperative Versus Postoperative Chemotherapy on the Extent and Number of Surgical Procedures in Patients Treated in Randomized Clinical Trials for Breast Cancer. Annals of Surgery, 2006, 244, 464-470.	4.2	135
79	Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer. Clinical Cancer Research, 2012, 18, 5816-5828.	7.0	135
80	The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer. Cancer, 2004, 101, 1514-1523.	4.1	134
81	Breast conservation after neoadjuvant chemotherapy. Cancer, 2005, 103, 689-695.	4.1	130
82	Predictors of Tumor Progression During Neoadjuvant Chemotherapy in Breast Cancer. Journal of Clinical Oncology, 2010, 28, 1821-1828.	1.6	128
83	Nodal Status and Clinical Outcomes in a Large Cohort of Patients With Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2011, 29, 2628-2634.	1.6	128
84	Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clinical Cancer Research, 2018, 24, 181-188.	7.0	127
85	Validation of a Breast Cancer Nomogram for Predicting Nonsentinel Lymph Node Metastases After a Positive Sentinel Node Biopsy. Annals of Surgical Oncology, 2006, 13, 310-320.	1.5	120
86	Futibatinib, an Irreversible FGFR1â€“4 Inhibitor, in Patients with Advanced Solid Tumors HarboringFGF/FGFRAberrations: A Phase I Dose-Expansion Study. Cancer Discovery, 2022, 12, 402-415.	9.4	119
87	Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. Clinical Cancer Research, 2022, 28, 677-688.	7.0	119
88	Intraoperative margin assessment reduces reexcision rates in patients with ductal carcinoma in situ treated with breast-conserving surgery. American Journal of Surgery, 2003, 186, 371-377.	1.8	118
89	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature Genetics, 2021, 53, 86-99.	21.4	118
90	Deciphering the Role of PI3K/Akt/mTOR Pathway in Breast Cancer Biology and Pathogenesis. Clinical Breast Cancer, 2010, 10, S59-S65.	2.4	116

#	Article	IF	Citations
91	Incorporation of Sentinel Lymph Node Metastasis Size Into a Nomogram Predicting Nonsentinel Lymph Node Involvement in Breast Cancer Patients With a Positive Sentinel Lymph Node. Annals of Surgery, 2012, 255, 109-115.	4.2	116
92	Prospective Evaluation of the Nippleâ€“Areola Complex Sparing Mastectomy for Risk Reduction and for Early-Stage Breast Cancer. Annals of Surgical Oncology, 2012, 19, 1137-1144.	1.5	116
93	Triple Receptorâ€“Negative Breast Cancer: The Effect of Race on Response to Primary Systemic Treatment and Survival Outcomes. Journal of Clinical Oncology, 2009, 27, 220-226.	1.6	115
94	Overcoming implementation challenges of personalized cancer therapy. Nature Reviews Clinical Oncology, 2012, 9, 542-548.	27.6	115
95	Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. Cancer Discovery, 2015, 5, 64-71.	9.4	115
96	Advances in Targeting Human Epidermal Growth Factor Receptor-2 Signaling for Cancer Therapy: Fig. 1.. Clinical Cancer Research, 2006, 12, 6326-6330.	7.0	114
97	Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncology, The, 2010, 11, 373-382.	10.7	114
98	Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. , 2017, 5, 100.		114
99	Multidisciplinary Considerations in the Implementation of the Findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: A Practice-Changing Trial. Annals of Surgical Oncology, 2011, 18, 2407-2412.	1.5	113
100	Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.. Journal of Clinical Oncology, 2019, 37, 2507-2507.	1.6	113
101	Improving local control with breast-conserving therapy. Cancer, 2005, 104, 20-29.	4.1	109
102	A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer. Clinical Cancer Research, 2011, 17, 6582-6591.	7.0	109
103	cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes. Clinical Cancer Research, 2012, 18, 2269-2277.	7.0	108
104	Trends for Inflammatory Breast Cancer: Is Survival Improving?. Oncologist, 2007, 12, 904-912.	3.7	106
105	Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Medicine, 2016, 14, 168.	5.5	106
106	Effects of Tissue Handling on RNA Integrity and Microarray Measurements From Resected Breast Cancers. Journal of the National Cancer Institute, 2011, 103, 1871-1883.	6.3	104
107	Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer. Molecular Cancer Therapeutics, 2014, 13, 1382-1389.	4.1	104
108	CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features. PLoS ONE, 2013, 8, e77945.	2.5	104

#	Article	IF	Citations
109	Contralateral prophylactic mastectomy. Cancer, 2004, 101, 1977-1986.	4.1	102
110	Building a Personalized Medicine Infrastructure at a Major Cancer Center. Journal of Clinical Oncology, 2013, 31, 1849-1857.	1.6	101
111	eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Molecular Cancer Therapeutics, 2008, 7, 1782-1788.	4.1	99
112	Role of Glycogen Synthase Kinase 3Î² in Rapamycin-Mediated Cell Cycle Regulation and Chemosensitivity. Cancer Research, 2005, 65, 1961-1972.	0.9	98
113	A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations. Clinical Cancer Research, 2019, 25, 2699-2707.	7.0	98
114	Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Research and Treatment, 2011, 130, 145-153.	2.5	96
115	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. Journal of Clinical Oncology, 2022, 40, 1231-1258.	1.6	96
116	mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer. Clinical Cancer Research, 2016, 22, 1699-1712.	7.0	95
117	Comparative Analysis of Sentinel Lymph Node Operation in Male and Female Breast Cancer Patients. Journal of the American College of Surgeons, 2006, 203, 475-480.	0.5	94
118	Triple-Negative Breast Cancer Is Not a Contraindication for Breast Conservation. Annals of Surgical Oncology, 2011, 18, 3164-3173.	1.5	93
119	Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers. Cancer Discovery, 2020, 10, 657-663.	9.4	93
120	Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis. Cancer, 2005, 104, 692-699.	4.1	92
121	Commonly cited website quality criteria are not effective at identifying inaccurate online information about breast cancer. Cancer, 2008, 112, 1206-1213.	4.1	92
122	Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. Oncotarget, 2015, 6, 12890-12908.	1.8	92
123	High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Research and Treatment, 2013, 137, 319-327.	2.5	90
124	Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Investigational New Drugs, 2018, 36, 601-607.	2.6	90
125	TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Modern Pathology, 2021, 34, 710-719.	5.5	90
126	Accuracy of the Combination of Mammography and Sonography in Predicting Tumor Response in Breast Cancer Patients After Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2006, 13, 1443-1449.	1.5	89

#	Article	IF	Citations
127	Immediate Breast Reconstruction can Impact Postmastectomy Irradiation. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 485-494.	1.3	88
128	Local, regional, and systemic recurrence rates in patients undergoing skinâ€sparing mastectomy compared with conventional mastectomy. Cancer, 2011, 117, 916-924.	4.1	87
129	Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget, 2015, 6, 12809-12821.	1.8	86
130	Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype. JCO Precision Oncology, 2018, 2, 1-12.	3.0	86
131	Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clinical Proteomics, 2011, 8, 11.	2.1	85
132	Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors. Clinical Chemistry, 2015, 61, 544-553.	3.2	85
133	Translation initiation in cancer: a novel target for therapy. Molecular Cancer Therapeutics, 2002, 1, 971-9.	4.1	85
134	Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor. Molecular Cancer Therapeutics, 2009, 8, 1157-1168.	4.1	83
135	Impact of Chemotherapy Sequencing on Local-Regional Failure Risk in Breast Cancer Patients Undergoing Breast-Conserving Therapy. Annals of Surgery, 2013, 257, 173-179.	4.2	83
136	Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Cancer Discovery, 2020, 10, 198-213.	9.4	83
137	Incidence and Prevention of Venous Thromboembolism in Patients Undergoing Breast Cancer Surgery and Treated According to Clinical Pathways. Annals of Surgery, 2006, 243, 96-101.	4.2	81
138	Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer, 2006, 107, 1440-1447.	4.1	79
139	Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. Journal of Clinical Oncology, 2018, 36, 3459-3465.	1.6	79
140	How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer?. Cancer, 2008, 113, 30-37.	4.1	78
141	BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Molecular Cancer Therapeutics, 2016, 15, 1397-1404.	4.1	78
142	Chest Wall Recurrence After Mastectomy Does Not Always Portend a Dismal Outcome. Annals of Surgical Oncology, 2003, 10, 628-634.	1.5	76
143	A novel automated assay for the rapid identification of metastatic breast carcinoma in sentinel lymph nodes. Cancer, 2011, 117, 2599-2607.	4.1	75
144	Everolimus in Advanced Pancreatic Neuroendocrine Tumors: The Clinical Experience. Cancer Research, 2013, 73, 1449-1453.	0.9	75

#	Article	IF	Citations
145	Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer. Cancer Research, 2021, 81, 5572-5581.	0.9	75
146	Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. American Journal of Surgery, 2007, 194, 527-531.	1.8	74
147	Present-Day Locoregional Control in Patients with T1 or T2 Breast Cancer with 0 and 1 to 3 Positive Lymph Nodes After Mastectomy Without Radiotherapy. Annals of Surgical Oncology, 2010, 17, 2899-2908.	1.5	74
148	Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53. Clinical Cancer Research, 2021, 27, 5236-5247.	7.0	74
149	HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Research and Treatment, 2009, 113, 501-507.	2.5	73
150	Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial. Clinical Cancer Research, 2013, 19, 5474-5484.	7.0	72
151	Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas.. Journal of Clinical Oncology, 2017, 35, 2505-2505.	1.6	71
152	Pagetâ€™s Disease of the Breast: There Is a Role for Breast-Conserving Therapy. Annals of Surgical Oncology, 2005, 12, 391-397.	1.5	70
153	Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic. Clinical Cancer Research, 2014, 20, 6336-6345.	7.0	70
154	Hotspot Mutation Panel Testing Reveals Clonal Evolution in a Study of 265 Paired Primary and Metastatic Tumors. Clinical Cancer Research, 2015, 21, 2644-2651.	7.0	70
155	Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. Clinical Cancer Research, 2018, 24, 6594-6610.	7.0	70
156	Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer, 2012, 118, 1498-1506.	4.1	69
157	Efficacy of Quality Criteria to Identify Potentially Harmful Information: A Cross-sectional Survey of Complementary and Alternative Medicine Web Sites. Journal of Medical Internet Research, 2004, 6, e21.	4.3	69
158	Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. American Journal of Surgery, 2008, 196, 81-87.	1.8	67
159	BikDD Eliminates Breast Cancer Initiating Cells and Synergizes with Lapatinib for Breast Cancer Treatment. Cancer Cell, 2011, 20, 341-356.	16.8	67
160	Biology, Treatment, and Outcome in Very Young and Older Women with DCIS. Annals of Surgical Oncology, 2012, 19, 3777-3784.	1.5	67
161	Primary Tumor Extirpation in Breast Cancer Patients Who Present with Stage IV Disease is Associated with Improved Survival. Annals of Surgical Oncology, 2013, 20, 1893-1899.	1.5	67
162	TransVar: a multilevel variant annotator for precision genomics. Nature Methods, 2015, 12, 1002-1003.	19.0	67

#	Article	IF	Citations
163	Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery. American Journal of Surgery, 2009, 198, 720-725.	1.8	66
164	A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer, 2010, 116, 2543-2548.	4.1	66
165	Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment. Cancer Letters, 2013, 334, 245-252.	7.2	65
166	RET Fusion as a Novel Driver of Medullary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 788-793.	3.6	65
167	Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS ONE, 2017, 12, e0173345.	2.5	65
168	Hepatocellular carcinoma: Where there is unmet need. Molecular Oncology, 2015, 9, 1501-1509.	4.6	64
169	Impact of the American College of Surgeons Oncology Group Z0011 Criteria Applied to a Contemporary Patient Population. Journal of the American College of Surgeons, 2013, 216, 105-113.	0.5	63
170	BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. Oncotarget, 2014, 5, 3607-3610.	1.8	63
171	Effective Local Control and Long-Term Survival in Patients with T4 Locally Advanced Breast Cancer Treated with Breast Conservation Therapy. Annals of Surgical Oncology, 2004, 11, 854-860.	1.5	62
172	Age and Survival Estimates in Patients Who Have Node-Negative T1ab Breast Cancer by Breast Cancer Subtype. Clinical Breast Cancer, 2011, 11, 325-331.	2.4	62
173	Gene Expression, Molecular Class Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast Cancer. Clinical Cancer Research, 2012, 18, 1109-1119.	7.0	62
174	Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Research, 2012, 14, R138.	5.0	62
175	Breast Cancer Multifocality and Multicentricity and Locoregional Recurrence. Oncologist, 2013, 18, 1167-1173.	3.7	62
176	Colocalized Delivery of Rapamycin and Paclitaxel to Tumors Enhances Synergistic Targeting of the PI3K/Akt/mTOR Pathway. Molecular Therapy, 2014, 22, 1310-1319.	8.2	62
177	Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget, 2017, 8, 39254-39267.	1.8	62
178	Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. American Journal of Surgery, 2006, 192, 552-555.	1.8	61
179	Association between clinical characteristics and riskâ€reduction interventions in women who underwent BRCA1 and BRCA2 testing. Cancer, 2006, 107, 2745-2751.	4.1	61
180	Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. Clinical Cancer Research, 2018, 24, 3263-3272.	7.0	61

#	Article	IF	Citations
181	Classification of Ipsilateral Breast Tumor Recurrences After Breast Conservation Therapy Can Predict Patient Prognosis and Facilitate Treatment Planning. Annals of Surgery, 2011, 253, 572-579.	4.2	60
182	Rapamycin Regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer. Molecular Cancer Therapeutics, 2010, 9, 2770-2784.	4.1	59
183	Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer, 2011, 117, 39-47.	4.1	59
184	HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer.. Journal of Clinical Oncology, 2016, 34, 3517-3517.	1.6	59
185	Polymorphisms and haplotypes of the NBS1 gene are associated with risk of sporadic breast cancer in non-Hispanic white women <=55 years. Carcinogenesis, 2006, 27, 2209-2216.	2.8	58
186	The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. Drug Discovery Today, 2015, 20, 1433-1438.	6.4	58
187	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nature Communications, 2021, 12, 5086.	12.8	58
188	Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer, 2008, 112, 2352-2358.	4.1	56
189	Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer, 2009, 115, 962-971.	4.1	56
190	Decreased TGFÎ² signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Research and Treatment, 2010, 119, 305-314.	2.5	56
191	Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. Oncotarget, 2014, 5, 8544-8557.	1.8	56
192	Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts. Annals of Translational Medicine, 2019, 7, 179-179.	1.7	56
193	Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected. Cancer Cell, 2006, 10, 89-91.	16.8	55
194	Rapamycin regulates the phosphorylation of rictor. Biochemical and Biophysical Research Communications, 2007, 362, 330-333.	2.1	55
195	Prognostic significance of HERâ€2 status in women with inflammatory breast cancer. Cancer, 2008, 112, 1905-1911.	4.1	54
196	Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracyclineâ€•and nonanthracyclineâ€based regimens for HER2â€positive breast cancer. Cancer, 2012, 118, 2385-2393.	4.1	54
197	Earlier age of onset of BRCA mutationâ€related cancers in subsequent generations. Cancer, 2012, 118, 321-325.	4.1	54
198	Precision Oncology Decision Support: Current Approaches and Strategies for the Future. Clinical Cancer Research, 2018, 24, 2719-2731.	7.0	54

#	Article	IF	Citations
199	Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clinical Cancer Research, 2019, 25, 6107-6118.	7.0	54
200	Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS ONE, 2015, 10, e0136851.	2.5	54
201	Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. Oncotarget, 2014, 5, 2349-2354.	1.8	54
202	MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget, 2016, 7, 54627-54631.	1.8	53
203	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clinical Cancer Research, 2017, 23, 3657-3666.	7.0	53
204	Molecular Landscape ofERBB2/ERBB3Mutated Colorectal Cancer. Journal of the National Cancer Institute, 2018, 110, 1409-1417.	6.3	53
205	Neoadjuvant Chemotherapy in Invasive Lobular Carcinoma May Not Improve Rates of Breast Conservation. Annals of Surgical Oncology, 2009, 16, 1606-1611.	1.5	50
206	Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clinical Cancer Research, 2017, 23, 5648-5656.	7.0	50
207	Personalized cancer therapyâ€"leveraging a knowledge base for clinical decision-making. Journal of Physical Education and Sports Management, 2018, 4, a001578.	1.2	50
208	Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clinical Cancer Research, 2020, 26, 1924-1931.	7.0	50
209	Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, 3014-3014.	1.6	50
210	FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors. PLoS ONE, 2014, 9, e89388.	2.5	50
211	Anaphylactoid Reactions to Isosulfan Blue Dye During Breast Cancer Lymphatic Mapping in Patients Given Preoperative Prophylaxis. Journal of Clinical Oncology, 2004, 22, 567-568.	1.6	49
212	Histologic changes associated with falseâ€negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph nodeâ€positive breast cancer before treatment. Cancer, 2010, 116, 2878-2883.	4.1	49
213	Frequency of mesenchymalâ€epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositideâ€3â€kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer, 2013, 119, 7-15.	4.1	49
214	Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer, 2004, 100, 942-949.	4.1	48
215	Incidence and Consequence of Close Margins in Patients with Ductal Carcinoma-In Situ Treated with Mastectomy: Is Further Therapy Warranted?. Annals of Surgical Oncology, 2013, 20, 4103-4112.	1.5	48
216	A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clinical Cancer Research, 2017, 23, 6468-6477.	7.0	48

#	Article	IF	Citations
217	Evaluation of the MD Anderson Prognostic Index for Local-Regional Recurrence After Breast Conserving Therapy in Patients Receiving Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2012, 19, 901-907.	1.5	47
218	Influence of Biospecimen Variables on Proteomic Biomarkers in Breast Cancer. Clinical Cancer Research, 2014, 20, 3870-3883.	7.0	47
219	Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence. Cancer, 2005, 104, 479-490.	4.1	46
220	Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist, 2018, 23, 1300-1309.	3.7	46
221	Validation of HER2 Amplification as a Predictive Biomarker for Antiâ€“Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. JCO Precision Oncology, 2019, 3, 1-13.	3.0	46
222	Attitudes toward molecular testing for personalized cancer therapy. Cancer, 2015, 121, 243-250.	4.1	45
223	Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. Breast Cancer Research, 2017, 19, 93.	5.0	45
224	Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open, 2020, 5, e000799.	4.5	45
225	BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget, 2015, 6, 26886-26894.	1.8	45
226	Usability of quality measures for online health information: Can commonly used technical quality criteria be reliably assessed?. International Journal of Medical Informatics, 2005, 74, 675-683.	3.3	44
227	The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer, 2006, 107, 1248-1254.	4.1	44
228	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget, 2016, 7, 67521-67531.	1.8	44
229	Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. JCO Precision Oncology, 2018, 2018, 1-15.	3.0	43
230	Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy. Expert Opinion on Investigational Drugs, 2018, 27, 741-751.	4.1	43
231	First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibodyâ€“Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer. Targeted Oncology, 2019, 14, 591-601.	3.6	43
232	Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial. Gynecologic Oncology, 2020, 159, 150-156.	1.4	43
233	Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. Journal of Thoracic Oncology, 2020, 15, 1611-1623.	1.1	43
234	Impact of Progression During Neoadjuvant Chemotherapy on Surgical Management of Breast Cancer. Annals of Surgical Oncology, 2011, 18, 932-938.	1.5	42

#	Article	IF	Citations
235	Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clinical Cancer Research, 2019, 25, 3802-3810.	7.0	42
236	Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. Oncologist, 2021, 26, 588-596.	3.7	42
237	Challenges and perspective of drug repurposing strategies in early phase clinical trials. Oncoscience, 2015, 2, 576-580.	2.2	42
238	Molecularâ€targeted nanotherapies in cancer: Enabling treatment specificity. Molecular Oncology, 2011, 5, 492-503.	4.6	41
239	Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy. Annals of Surgical Oncology, 2017, 24, 652-659.	1.5	41
240	Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget, 2015, 6, 20099-20110.	1.8	41
241	Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. Discovery Medicine, 2014, 17, 101-14.	0.5	41
242	Lymphatic Drainage Patterns on Early Versus Delayed Breast Lymphoscintigraphy Performed after Injection of Filtered Tc-99m Sulfur Colloid in Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy. Clinical Nuclear Medicine, 2005, 30, 11-15.	1.3	40
243	Lymphovascular Invasion and Lobular Histology are Associated with Increased Incidence of Isolated Tumor Cells in Sentinel Lymph Nodes from Early-Stage Breast Cancer Patients. Annals of Surgical Oncology, 2008, 15, 3369-3377.	1.5	40
244	Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.. Journal of Clinical Oncology, 2021, 39, 299-299.	1.6	40
245	Bias from removing read duplication in ultra-deep sequencing experiments. Bioinformatics, 2014, 30, 1073-1080.	4.1	39
246	Improving the detection of patients with inherited predispositions to hematologic malignancies using nextâ€generation sequencingâ€based leukemia prognostication panels. Cancer, 2018, 124, 2704-2713.	4.1	39
247	Lower and central tumor location correlates with lymphoscintigraphy drainage to the internal mammary lymph nodes in breast carcinoma. Cancer, 2005, 103, 1323-1329.	4.1	38
248	Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy. Cancer, 2008, 112, 2646-2654.	4.1	38
249	Impact of Identification of Internal Mammary Sentinel Lymph Node Metastasis in Breast Cancer Patients. Annals of Surgical Oncology, 2014, 21, 60-65.	1.5	38
250	High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype. Clinical Cancer Research, 2016, 22, 5068-5078.	7.0	38
251	Use of Lymphoscintigraphy Defines Lymphatic Drainage Patterns Before Sentinel Lymph Node Biopsy for Breast Cancer. Journal of the American College of Surgeons, 2006, 203, 64-72.	0.5	37
252	Delays in Primary Surgical Treatment Are Not Associated With Significant Tumor Size Progression in Breast Cancer Patients. Annals of Surgery, 2011, 254, 119-124.	4.2	37

#	Article	IF	Citations
253	Polymer Nanoparticles Encased in a Cyclodextrin Complex Shell for Potential Siteâ€•and Sequenceâ€Specific Drug Release. Advanced Functional Materials, 2014, 24, 4753-4761.	14.9	36
254	Signature program: a platform of basket trials. Oncotarget, 2018, 9, 21383-21395.	1.8	36
255	Characteristics and Outcome of AKT1E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry. Cancer Discovery, 2020, 10, 526-535.	9.4	36
256	Potential applicability of balloon catheter-based accelerated partial breast irradiation after conservative surgery for breast carcinoma. Cancer, 2004, 100, 490-498.	4.1	34
257	Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast Cancer Research and Treatment, 2009, 117, 61-68.	2.5	34
258	Regulation and localization of ribosomal protein S6 kinase 1 isoforms. Growth Factors, 2009, 27, 12-21.	1.7	34
259	Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing. American Journal of Clinical Pathology, 2015, 144, 713-721.	0.7	34
260	Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors. Oncoscience, 2016, 3, 164-172.	2.2	34
261	Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemotherapy and Pharmacology, 2016, 77, 973-977.	2.3	34
262	Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. Clinical Cancer Research, 2017, 23, 4027-4034.	7.0	34
263	Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. Hepatobiliary Surgery and Nutrition, 2019, 8, 604-614.	1.5	34
264	Functional consequence of theMET-T1010I polymorphism in breast cancer. Oncotarget, 2015, 6, 2604-2614.	1.8	34
265	Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. Cancer Discovery, 2022, 12, 654-669.	9.4	34
266	RNA-binding specificity of Y-box protein 1. RNA Biology, 2009, 6, 59-64.	3.1	33
267	High Prevalence of Preinvasive Lesions Adjacent to BRCA1/2-Associated Breast Cancers. Cancer Prevention Research, 2009, 2, 122-127.	1.5	33
268	Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer. Cancer, 2012, 118, 6287-6296.	4.1	33
269	Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (SutentÂ®) a VEGFR2/PDGFRÎ²/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. Journal of Hematology and Oncology, 2014, 7, 52.	17.0	33
270	Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes. Clinical Breast Cancer, 2015, 15, 153-160.	2.4	33

#	Article	IF	Citations
271	Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer. Clinical Cancer Research, 2021, 27, 1681-1694.	7.0	33
272	Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer, 2009, 115, 1598-1604.	4.1	31
273	Cancer Risk Management Decisions of Women with BRCA1 or BRCA2 Variants of Uncertain Significance. Breast Journal, 2011, 17, 210-212.	1.0	31
274	Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents. Molecular Cancer Therapeutics, 2014, 13, 3175-3184.	4.1	31
275	â€œPersonalized Cancer Therapyâ€: A Publicly Available Precision Oncology Resource. Cancer Research, 2017, 77, e123-e126.	0.9	31
276	Phase II, 2â€stage, 2â€arm, PIK3CA mutation stratified trial of MKâ€2206 in recurrent endometrial cancer. International Journal of Cancer, 2020, 147, 413-422.	5.1	31
277	First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. Breast Cancer Research, 2021, 23, 29.	5.0	31
278	SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer. Journal of the National Cancer Institute, 2015, 107, .	6.3	30
279	Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. Molecular Cancer Therapeutics, 2018, 17, 1595-1601.	4.1	30
280	Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. Oncologist, 2019, 24, 219-228.	3.7	30
281	Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway.. Journal of Clinical Oncology, 2017, 35, 676-676.	1.6	30
282	A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L).. Journal of Clinical Oncology, 2018, 36, 11514-11514.	1.6	30
283	Is intraoperative touch imprint cytology of sentinel lymph nodes in patients with breast cancer cost effective?. Cancer, 2006, 107, 2328-2336.	4.1	29
284	Does Blue Dye Contribute to Success of Sentinel Node Mapping for Breast Cancer?. Annals of Surgical Oncology, 2010, 17, 280-285.	1.5	29
285	Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit. Clinical Breast Cancer, 2014, 14, 468-474.	2.4	29
286	Clinical activity of ceritinib in ROS1 -rearranged non-small cell lung cancer: Bench to bedside report. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E1419-20.	7.1	29
287	Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. British Journal of Cancer, 2018, 118, 763-769.	6.4	28
288	Challenges with biomarkers in cancer drug discovery and development. Expert Opinion on Drug Discovery, 2018, 13, 685-690.	5.0	28

#	Article	IF	Citations
289	Abstract CT010: Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements. Cancer Research, 2021, 81, CT010-CT010.	0.9	28
290	Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget, 2018, 9, 19891-19899.	1.8	28
291	Clinical and Molecular Characterization ofPOLEMutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. JCO Precision Oncology, 2022, 6, e2100267.	3.0	28
292	Attitudes regarding privacy of genomic information in personalized cancer therapy. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, e320-e325.	4.4	27
293	Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Research and Treatment, 2017, 163, 263-272.	2.5	27
294	MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget, 2014, 5, 1837-1845.	1.8	27
295	The rapamycin-regulated gene expression signature determines prognosis for breast cancer. Molecular Cancer, 2009, 8, 75.	19.2	26
296	Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. Endocrine-Related Cancer, 2015, 22, 431-441.	3.1	26
297	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight, 2017, 2, .	5.0	26
298	Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. Molecular Cancer Therapeutics, 2019, 18, 1149-1157.	4.1	26
299	OCTANE: Oncology Clinical Trial Annotation Engine. JCO Clinical Cancer Informatics, 2019, 3, 1-11.	2.1	26
300	Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC).. Journal of Clinical Oncology, 2016, 34, 4568-4568.	1.6	26
301	Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget, 2018, 9, 33232-33243.	1.8	26
302	Decision analysis to assess the efficacy of routine sentinel lymphadenectomy in patients undergoing prophylactic mastectomy. Cancer, 2007, 110, 2542-2550.	4.1	25
303	Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer. Cancer, 2012, 118, 4936-4943.	4.1	25
304	MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience, 2013, 1, 5-13.	2.2	25
305	Molecular therapeutics: promise and challenges. Seminars in Oncology, 2004, 31, 39-53.	2.2	24
306	Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer, 2006, 106, 42-50.	4.1	24

#	Article	IF	Citations
307	Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged â‰¤55 years. Breast Cancer Research and Treatment, 2008, 110, 357-366.	2.5	24
308	Epithelial to mesenchymal transition is associated with rapamycin resistance. Oncotarget, 2015, 6, 19500-19513.	1.8	24
309	A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. Clinical Cancer Research, 2021, 27, 3050-3060.	7.0	24
310	A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors. Clinical Cancer Research, 2021, 27, 4994-5003.	7.0	24
311	Prognostic Value of Initial Clinical Disease Stage After Achieving Pathological Complete Response. Oncologist, 2008, 13, 6-15.	3.7	23
312	Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer, 2012, 118, 1515-1522.	4.1	23
313	Extracting genetic alteration information for personalized cancer therapy from ClinicalTrials.gov. Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 750-757.	4.4	23
314	Cancer driver mutation prediction through Bayesian integration of multi-omic data. PLoS ONE, 2018, 13, e0196939.	2.5	23
315	Differential Outcomes in Codon 12/13 and Codon 61NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients withNRAS-Mutated Tumors. Clinical Cancer Research, 2021, 27, 2996-3004.	7.0	23
316	Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. BMC Cancer, 2008, 8, 101.	2.6	22
317	Clinical Use of Precision Oncology Decision Support. JCO Precision Oncology, 2017, 2017, 1-12.	3.0	22
318	Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial. JCO Precision Oncology, 2021, 5, 133-144.	3.0	22
319	Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC).. Journal of Clinical Oncology, 2013, 31, 5524-5524.	1.6	22
320	Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget, 2016, 7, 76362-76373.	1.8	22
321	High-resolution fiber optic microscopy with fluorescent contrast enhancement for the identification of axillary lymph node metastases in breast cancer: a pilot study. Biomedical Optics Express, 2010, 1, 911.	2.9	21
322	Other Primary Malignancies in Breast Cancer Patients Treated with Breast Conserving Surgery and Radiation Therapy. Annals of Surgical Oncology, 2013, 20, 1514-1521.	1.5	21
323	Genotype-Phenotype Correlations by Ethnicity and Mutation Location inBRCAMutation Carriers. Breast Journal, 2015, 21, 260-267.	1.0	21
324	Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Scientific Reports, 2017, 7, 15963.	3.3	21

#	Article	IF	Citations
325	Detection of Pathogenic Germline Variants Among Patients With Advanced Colorectal Cancer Undergoing Tumor Genomic Profiling for Precision Medicine. Diseases of the Colon and Rectum, 2019, 62, 429-437.	1.3	21
326	Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.. Journal of Clinical Oncology, 2021, 39, 164-164.	1.6	21
327	Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. Scientific Reports, 2020, 10, 22087.	3.3	21
328	Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial. Clinical Cancer Research, 2022, 28, 1540-1548.	7.0	21
329	Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines. JAMA Network Open, 2022, 5, e2213070.	5.9	21
330	Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Medicine, 2016, 5, 3437-3444.	2.8	20
331	Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precision Oncology, 2019, 3, 1-12.	3.0	20
332	A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas.. Journal of Clinical Oncology, 2016, 34, 2581-2581.	1.6	20
333	Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget, 2014, 5, 9049-9064.	1.8	20
334	Patient knowledge and information-seeking about personalized cancer therapy. International Journal of Medical Informatics, 2016, 88, 52-57.	3.3	19
335	Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis. Journal of Cancer, 2018, 9, 3640-3646.	2.5	19
336	Comparison of Real-Time Fluorescence Confocal Digital Microscopy With Hematoxylin-Eosinâ€“Stained Sections of Core-Needle Biopsy Specimens. JAMA Network Open, 2020, 3, e200476.	5.9	19
337	Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapy. JCI Insight, 2016, 1, e90733.	5.0	19
338	Differences in Gene and Protein Expression and the Effects of Race/Ethnicity on Breast Cancer Subtypes. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 316-323.	2.5	18
339	Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Clinical Breast Cancer, 2015, 15, 325-331.	2.4	18
340	MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors. Clinical Genitourinary Cancer, 2015, 13, e19-e26.	1.9	18
341	Automated identification of molecular effects of drugs (AIMED). Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 758-765.	4.4	18
342	Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemotherapy and Pharmacology, 2016, 78, 167-171.	2.3	18

#	Article	IF	Citations
343	Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. Journal of Cutaneous Pathology, 2018, 45, 786-790.	1.3	18
344	Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. European Journal of Cancer, 2019, 120, 54-64.	2.8	18
345	Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. Oncologist, 2021, 26, 558-e1098.	3.7	18
346	Effectiveness and Safety of Magseed Localization for Excision of Breast Lesions. Annals of Surgery Open, 2020, 1, e008.	1.4	18
347	Praluzatamab Ravtansine, a CD166-Targeting Antibodyâ€“Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clinical Cancer Research, 2022, 28, 2020-2029.	7.0	18
348	Breast cancer in the very elderly: treatment patterns and complications in a tertiary cancer center. American Journal of Surgery, 2006, 192, 541-544.	1.8	17
349	Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer. American Journal of Surgery, 2009, 198, 387-391.	1.8	17
350	Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Investigational New Drugs, 2018, 36, 416-423.	2.6	17
351	Phase I Study of P-cadherinâ€“targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors. Clinical Cancer Research, 2020, 26, 5830-5842.	7.0	17
352	Targeted therapy for gastrointestinal (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 653-653.	1.6	17
353	Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget, 2016, 7, 64421-64430.	1.8	17
354	Targeting PI3KÎ² alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss. Oncotarget, 2020, 11, 969-981.	1.8	17
355	Heterogenic Loss of BRCA in Breast Cancer: The â€œTwo-Hitâ€•Hypothesis Takes a Hit. Annals of Surgical Oncology, 2007, 14, 2428-2429.	1.5	16
356	Toward nodal staging of axillary lymph node basins through intradermal administration of fluorescent imaging agents. Biomedical Optics Express, 2014, 5, 183.	2.9	16
357	Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors. Journal of the National Cancer Institute, 2017, 109, .	6.3	16
358	Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers. Annals of Diagnostic Pathology, 2018, 35, 69-76.	1.3	16
359	Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy. JAMA Oncology, 2019, 5, 45.	7.1	16
360	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clinical Cancer Research, 2020, 26, 5579-5587.	7.0	16

#	Article	IF	Citations
361	Haplotype Analysis of the T-Cell Receptor Beta (TCRB) Locus by Long-amplicon TCRB Repertoire Sequencing. Journal of Immunotherapy and Precision Oncology, 2019, 2, 137-143.	1.4	16
362	The Effect of Leucine Restriction on Akt/mTOR Signaling in Breast Cancer Cell Lines In Vitro and In Vivo. Nutrition and Cancer, 2011, 63, 264-271.	2.0	15
363	Toronto Workshop on Late Recurrence in Estrogen Receptorâ€“Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI Cancer Spectrum, 2019, 3, pkz050.	2.9	15
364	Prospective Clinical Sequencing of Adult Glioma. Molecular Cancer Therapeutics, 2019, 18, 991-1000.	4.1	15
365	Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology. JCO Clinical Cancer Informatics, 2019, 3, 1-12.	2.1	15
366	Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity. Journal of the American Medical Informatics Association: JAMIA, 2020, 27, 1808-1812.	4.4	15
367	Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study. Oncotarget, 2019, 10, 6526-6535.	1.8	15
368	Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. JCO Precision Oncology, 2022, , .	3.0	15
369	Searching for cancer-related information online: Unintended retrieval of complementary and alternative medicine information. International Journal of Medical Informatics, 2005, 74, 685-693.	3.3	14
370	Disseminated Tumor Cells in Biologic Subtypes of Stage Iâ€“III Breast Cancer Patients. Annals of Surgical Oncology, 2010, 17, 3252-3258.	1.5	14
371	Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs. Clinical Cancer Research, 2017, 23, 4020-4026.	7.0	14
372	Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 3243-3252.	7.0	14
373	Determinants of mastectomy in breast conservation therapy candidates. American Journal of Surgery, 2005, 190, 602-605.	1.8	13
374	ClinSeK: a targeted variant characterization framework for clinical sequencing. Genome Medicine, 2015, 7, 34.	8.2	13
375	Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies. JCO Precision Oncology, 2018, 2, 1-12.	3.0	13
376	Clinically relevant inflammatory breast cancer patient-derived xenograftâ€“derived ex vivo model for evaluation of tumor-specific therapies. PLoS ONE, 2018, 13, e0195932.	2.5	13
377	Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. Clinical Cancer Research, 2019, 25, 7381-7387.	7.0	13
378	Precision Medicine in Oncologyâ€”Toward the Integrated Targeting of Somatic and Germline Genomic Aberrations. JAMA Oncology, 2021, 7, 507.	7.1	13

#	Article	IF	Citations
379	FGFR1Î² is a driver isoform of FGFR1 alternative splicing in breast cancer cells. Oncotarget, 2019, 10, 30-44.	1.8	13
380	Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. Journal of Medical Internet Research, 2019, 21, e10348.	4.3	13
381	Sentinel lymph node dissection provides axillary control equal to complete axillary node dissection in breast cancer patients with lobular histology and a negative sentinel node. American Journal of Surgery, 2005, 190, 598-601.	1.8	12
382	False Negative Rate of Sentinel Lymph Node Biopsy in Multicentric and Multifocal Breast Cancers May be Higher in Cases with Large Additive Tumor Burden. Breast Journal, 2009, 15, 645-648.	1.0	12
383	Surgical Patterns of Care in Patients with Invasive Breast Cancer Treated with Neoadjuvant Systemic Therapy and Breast Magnetic Resonance Imaging: Results of a Secondary Analysis of TBCRC 017. Annals of Surgical Oncology, 2015, 22, 75-81.	1.5	12
384	Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Scientific Reports, 2016, 6, 35448.	3.3	12
385	Early clinical efficacy of TAS-120, a covalently bound FGFR inhibitor, in patients with cholangiocarcinoma. Annals of Oncology, 2017, 28, iii145.	1.2	12
386	HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features. Human Pathology, 2019, 92, 32-38.	2.0	12
387	Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers. JCO Precision Oncology, 2019, 3, 1-14.	3.0	12
388	COVID-19 Pandemic and Surgical Oncology: Preserving the Academic Mission. Annals of Surgical Oncology, 2020, 27, 2591-2599.	1.5	12
389	Antibody-Drug Conjugates: Patient and Treatment Selection. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 105-114.	3.8	12
390	A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget, 2017, 8, 41806-41814.	1.8	12
391	Breast conservation in breast cancer: surgical and adjuvant considerations. Current Opinion in Obstetrics and Gynecology, 2004, 16, 31-36.	2.0	11
392	Career track of Society of University Surgeons Resident Research Award recipients. Journal of Surgical Research, 2013, 185, 92-96.	1.6	11
393	Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual. Clinical Cancer Research, 2017, 23, 1407-1413.	7.0	11
394	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI Cancer Spectrum, 2019, 3, pkz049.	2.9	11
395	Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations. Oncogene, 2021, 40, 4425-4439.	5.9	11
396	Potential Role of Mammalian Target of Rapamycin Inhibitors in Breast Cancer Therapy. Clinical Breast Cancer, 2005, 6, 357-360.	2.4	10

#	Article	IF	Citations
397	Validation of a Breast Cancer Nomogram for Predicting Nonsentinel Lymph Node Metastases after a Positive Sentinel Node Biopsy. Annals of Surgical Oncology, 2007, 14, 2422-2423.	1.5	10
398	The Impact of Tumor Heterogeneity on Patient Treatment Decisions. Clinical Chemistry, 2013, 59, 38-40.	3.2	10
399	Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience. Investigational New Drugs, 2017, 35, 59-67.	2.6	10
400	Physician interpretation of genomic test results and treatment selection. Cancer, 2018, 124, 966-972.	4.1	10
401	Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF â€mutated melanoma and other advanced malignancies. Cancer, 2019, 125, 463-472.	4.1	10
402	A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. Targeted Oncology, 2021, 16, 569-589.	3.6	10
403	A phase II and co-clinical study of an AKT inhibitor in patients (pts) with biomarker-enriched, previously treated metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 3563-3563.	1.6	10
404	Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion.. Journal of Clinical Oncology, 2016, 34, 9069-9069.	1.6	10
405	Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified. Cancer, 2022, 128, 509-518.	4.1	10
406	Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. JCO Precision Oncology, 2022, 6, e2100197.	3.0	10
407	Using Ontology Fingerprints to disambiguate gene name entities in the biomedical literature. Database: the Journal of Biological Databases and Curation, 2015, 2015, bav034-bav034.	3.0	9
408	Molecular determinants of post-mastectomy breast cancer recurrence. Npj Breast Cancer, 2018, 4, 34.	5.2	9
409	Expanded Analysis of Secondary Germline Findings From Matched Tumor/Normal Sequencing Identifies Additional Clinically Significant Mutations. JCO Precision Oncology, 2019, 3, 1-11.	3.0	9
410	Next generation sequencing for biliary tract cancers. Expert Review of Gastroenterology and Hepatology, 2021, 15, 471-474.	3.0	9
411	Outcome analysis of Phase I trial patients with metastaticKRASand/orTP53mutant non-small cell lung cancer. Oncotarget, 2018, 9, 33258-33270.	1.8	9
412	Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget, 2016, 7, 35132-35143.	1.8	9
413	A functional genomic approach to actionable gene fusions for precision oncology. Science Advances, 2022, 8, eabm2382.	10.3	9
414	Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival. Breast Cancer Research and Treatment, 2010, 123, 597-605.	2.5	8

#	Article	IF	Citations
415	Accelerated Approval and Breakthrough Therapy Designation: Oncology Drug Development on Speed?. Clinical Cancer Research, 2013, 19, 4305-4308.	7.0	8
416	Promising Rationally Derived Combination Therapy with PI3K and CDK4/6 Inhibitors. Cancer Cell, 2014, 26, 7-9.	16.8	8
417	Adapting a natural language processing tool to facilitate clinical trial curation for personalized cancer therapy. AMIA Summits on Translational Science Proceedings, 2014, 2014, 126-31.	0.4	8
418	Translation Initiation Factor 4E (eIF4E): Prognostic Marker and Potential Therapeutic Target. Annals of Surgical Oncology, 2008, 15, 2996-2997.	1.5	7
419	Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Research and Treatment, 2012, 133, 1131-1141.	2.5	7
420	Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. British Journal of Cancer, 2018, 118, 1419-1424.	6.4	7
421	Integrated transcriptomicâ€“genomic tool Texomer profiles cancer tissues. Nature Methods, 2019, 16, 401-404.	19.0	7
422	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. Molecular Cancer Research, 2021, 19, 395-402.	3.4	7
423	Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A PhaseÂII Trial. Advances in Therapy, 2021, 38, 4581-4591.	2.9	7
424	Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel. Oncotarget, 2016, 7, 71686-71695.	1.8	7
425	PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery. NAR Cancer, 2022, 4, zcac014.	3.1	7
426	Risk of Ipsilateral and Contralateral Cancer in BRCA Mutation Carriers with Breast Cancer. Current Breast Cancer Reports, 2011, 3, 151-155.	1.0	6
427	Genotype inBRCA-associated Breast Cancers. Breast Journal, 2013, 19, 87-91.	1.0	6
428	Two Birds With One Stone: Octreotide Treatment for Acromegaly and Breast Cancer. Journal of Clinical Oncology, 2013, 31, e398-e400.	1.6	6
429	Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer. Annals of Diagnostic Pathology, 2014, 18, 266-270.	1.3	6
430	Ploidy-Seq: inferring mutational chronology by sequencing polyploid tumor subpopulations. Genome Medicine, 2015, 7, 6.	8.2	6
431	Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. JCO Precision Oncology, 2019, 3, 1-10.	3.0	6
432	Doseâ€escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAFâ€mutated advanced cancers. Cancer, 2021, 127, 391-402.	4.1	6

#	Article	IF	Citations
433	Abstract CT024: Results of a phase I dose escalation study of ARQ 751 in adult subjects with advanced solid tumors with AKT1, 2, 3 genetic alterations, activating PI3K mutations, PTEN-null, or other known actionable PTEN mutations. Cancer Research, 2018, 78, CT024-CT024.	0.9	6
434	Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type Peripheral T-Cell Lymphoma. Blood, 2018, 132, 1623-1623.	1.4	6
435	Next-generation sequencing for the general cancer patient. Clinical Advances in Hematology and Oncology, 2019, 17, 447-454.	0.3	6
436	Sentinel Lymph Node Dissection Is Technically Feasible in Older Breast Cancer Patients. Clinical Breast Cancer, 2010, 10, 477-482.	2.4	5
437	The role of surgeons in building a personalized medicine program. Journal of Surgical Oncology, 2015, 111, 3-8.	1.7	5
438	A Cost Analysis of Preoperative Breast MRI Use for Patients with Invasive Lobular Cancer. Annals of Surgical Oncology, 2016, 23, 23-29.	1.5	5
439	Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center. JCO Clinical Cancer Informatics, 2018, 2, 1-14.	2.1	5
440	Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptorâ˜positive Metastatic Breast Cancer or Other Solid Tumors. Clinical Cancer Research, 2021, 27, 1247-1255.	7.0	5
441	Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multiâ€arm phase Ib study. Investigational New Drugs, 2021, 39, 1357-1365.	2.6	5
442	Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. Journal of Immunotherapy and Precision Oncology, 2021, 4, 45-52.	1.4	5
443	O2-1 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study*. Annals of Oncology, 2021, 32, S285.	1.2	5
444	Safety, toxicity and activity of multi-kinase inhibitor vandetanib in combination with everolimus in advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 9073-9073.	1.6	5
445	Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget, 2017, 8, 33796-33806.	1.8	5
446	A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. Gynecologic Oncology Reports, 2022, 40, 100974.	0.6	5
447	Reply to K.J. Van Zee et al. Journal of Clinical Oncology, 2012, 30, 3144-3145.	1.6	4
448	Whole Genome Sequencing in Cancer Clinics. EBioMedicine, 2015, 2, 15-16.	6.1	4
449	Exposure to antiâ€PDâ€1 causes functional differences in tumorâ€infiltrating lymphocytes in rare solid tumors. European Journal of Immunology, 2019, 49, 2245-2251.	2.9	4
450	FGFR pathway genetic aberrations in cholangiocarcinoma: Demographics and experience with targeted therapy.. Journal of Clinical Oncology, 2016, 34, 109-109.	1.6	4

#	Article	IF	Citations
451	Natural Language Processingâ€“Assisted Literature Retrieval and Analysis for Combination Therapy in Cancer. JCO Clinical Cancer Informatics, 2022, 6, e2100109.	2.1	4
452	Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors. Experimental Hematology and Oncology, 2021, 10, 59.	5.0	4
453	Serum Proteomics for BRCA1-associated Breast Cancer. Annals of Surgical Oncology, 2004, 11, 883-884.	1.5	3
454	Intra-Individual Comparison of Lymphatic Drainage Patterns Using Subareolar and Peritumoral Isotope Injection for Breast Cancer. Annals of Surgical Oncology, 2010, 17, 220-227.	1.5	3
455	Locoregional Interaction of Ixabepilone (Ixempra) After Breast Cancer Radiation. Oncologist, 2013, 18, 265-270.	3.7	3
456	Active Disclosure of Secondary Germline Findings to Deceased Research Participantsâ€™ Personal Representatives: Process and Outcomes. JCO Precision Oncology, 2017, 1, 1-5.	3.0	3
457	Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer. European Journal of Cancer, 2018, 89, 64-71.	2.8	3
458	Rate of change in investigational treatment options: An analysis of reports from a large precision oncology decision support effort. International Journal of Medical Informatics, 2020, 143, 104261.	3.3	3
459	Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy. Annals of Surgical Oncology, 2021, 28, 5477-5485.	1.5	3
460	Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study. Investigational New Drugs, 2022, 40, 290-299.	2.6	3
461	Surgical Options for Breast Cancer. , 2008, , 197-234.		3
462	TAK228 enhances antitumor activity of eribulin in triple negative breast cancer. Oncotarget, 2019, 10, 5011-5019.	1.8	3
463	MK-2206 window of opportunity study in breast cancer. Annals of Translational Medicine, 2018, 6, S57-S57.	1.7	3
464	Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Scientific Reports, 2022, 12, 1248.	3.3	3
465	Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. Clinical Cancer Research, 2022, , .	7.0	3
466	Natural History and Characteristics of ERBB2-mutated Hormone Receptorâ€“positive Metastatic Breast Cancer: A Multi-institutional Retrospective Caseâ€“control Study from AACR Project GENIE. Clinical Cancer Research, 2022, 28, 2118-2130.	7.0	3
467	A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. OncoTargets and Therapy, 2021, Volume 14, 3037-3049.	2.0	2
468	Genomic alterations driving breast cancer (BC) metastases and their relationship with the subtype switch in the GEICAM ConvertHER study.. Journal of Clinical Oncology, 2017, 35, 1017-1017.	1.6	2

#	Article	IF	Citations
469	Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition. Npj Precision Oncology, 2021, 5, 99.	5.4	2
470	Currency of online breast cancer information. Studies in Health Technology and Informatics, 2007, 129, 973-6.	0.3	2
471	Targeting translation initiation in breast cancer. Translation, 2014, 2, e28968.	2.9	1
472	Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy. International Journal of Radiation Oncology Biology Physics, 2016, 96, 637-644.	0.8	1
473	Reply to M.P. Decatris et al. Journal of Clinical Oncology, 2016, 34, 886-886.	1.6	1
474	Reply to J.J. Tao et al. Journal of Clinical Oncology, 2018, 36, 2451-2451.	1.6	1
475	Rapamycinâ€ˆâ€™â€mTORâ€+â€BRAFâ€=â€? Using relational similarity to find therapeutically relevant drug-gene relationships in unstructured text. Journal of Biomedical Informatics, 2019, 90, 103094.	4.3	1
476	Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open, 2020, 5, e001073.	4.5	1
477	Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clinical Genitourinary Cancer, 2022, 20, e16-e24.	1.9	1
478	Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients. Blood, 2013, 122, 3048-3048.	1.4	1
479	Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma. Journal of Immunotherapy and Precision Oncology, 2022, 5, 26-30.	1.4	1
480	Eukaryotic Initiation Factor 4E (eIF4E) can be effectively downregulated using small interfering RNA (siRNA), inhibiting growth in breast cancer cells. Journal of the American College of Surgeons, 2007, 205, S92-S93.	0.5	0
481	Intraoperative Margin Analysis in Breast-Conserving Surgery. Breast Diseases, 2008, 19, 25-26.	0.0	0
482	Reply: Strategy for Nonresponder Breast Cancer Patients to Neoadjuvant Treatment. Annals of Surgical Oncology, 2011, 18, 288-289.	1.5	0
483	HER2 studies look promising. Cancer, 2011, 117, 1109-1109.	4.1	0
484	Chemotherapy: Polymer Nanoparticles Encased in a Cyclodextrin Complex Shell for Potential Siteâ€•and Sequenceâ€Specific Drug Release (Adv. Funct. Mater. 30/2014). Advanced Functional Materials, 2014, 24, 4868-4868.	14.9	0
485	Next-Generation Sequencing: How Close Are We to Clinical Application?. Breast Diseases, 2014, 25, 296-299.	0.0	0
486	Reply to Letter. Annals of Surgery, 2014, 259, e50.	4.2	0

#	Article	IF	Citations
487	46. ClinGen somatic cancer working group: Enhancing standardized interpretation of cancer genetic data for clinical use. Cancer Genetics, 2020, 244, 17-18.	0.4	0
488	Prospecting whole cancer genomes. Nature Cancer, 2020, 1, 273-275.	13.2	0
489	Comparison of Mutation Profile Among Responders and Non-Responders in a Cohort of Patients with Relapsed/Refractory Myeloid Malignancies Treated with MEK 1/2 Inhibitor Trametinib. Blood, 2015, 126, 1386-1386.	1.4	0
490	Combination Therapies Targeting the PI3K/AKT/mTOR Pathways. Cancer Drug Discovery and Development, 2016, , 151-180.	0.4	0
491	Co-occurring genomic alterations and association with progression free survival in BRAFV600 mutated non-melanoma tumors treated with BRAF inhibitor.. Journal of Clinical Oncology, 2016, 34, 2546-2546.	1.6	0
492	Phase I trial of paclitaxel, bevacizumab, and temsirolimus in advanced solid malignancies.. Journal of Clinical Oncology, 2016, 34, 2573-2573.	1.6	0
493	Clinical utilization of precision oncology decision support for genomically-informed cancer therapy.. Journal of Clinical Oncology, 2016, 34, 11605-11605.	1.6	0
494	Clinical next-generation sequencing in sarcomas.. Journal of Clinical Oncology, 2016, 34, 11046-11046.	1.6	0
495	Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget, 2017, 8, 87163-87173.	1.8	0
496	Incorporating Precision Medicine into Phase I Clinical Trials. , 2020, , 221-231.		0
497	ASO Visual Abstract: Clinical Course of Breast Cancer Patients with Local Regional Progression During Neoadjuvant Systemic Therapy. Annals of Surgical Oncology, 2021, , 1.	1.5	0
498	Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study. Journal of Immunotherapy and Precision Oncology, 2022, 5, 10-12.	1.4	0